Related Experiment Video
Updated: May 23, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Novel antithrombotic agents for atrial fibrillation
Maria M Niespialowska-Steuden1, Vias Markides, Diana A Gorog
1Department of Cardiology, East & North Hertfordshire NHS Trust, Herts, UK.
Pharmacology & Therapeutics
|April 3, 2012
Summary
Atrial fibrillation (AF) patients face high stroke risk. Novel oral anticoagulants offer improved convenience and efficacy over warfarin, though monitoring challenges remain.
Area of Science:
- Cardiology
- Pharmacology
- Thrombosis
Background:
- Atrial fibrillation (AF) is a common arrhythmia, significantly increasing stroke risk.
- Vitamin K antagonists like warfarin have been standard for AF stroke prevention but have limitations.
- Warfarin's limitations include narrow therapeutic range, need for monitoring, and bleeding risks.
Purpose of the Study:
- To review traditional and novel thromboprophylaxis strategies for atrial fibrillation.
- To evaluate the efficacy and limitations of current and emerging anticoagulant therapies.
Main Methods:
- Literature review of clinical studies on anticoagulants for AF.
- Comparative analysis of vitamin K antagonists and novel oral anticoagulants.
- Evaluation of drug mechanisms, clinical trial outcomes, and practical considerations.
Main Results:
- Novel oral anticoagulants (NOACs) include direct thrombin inhibitors and factor Xa inhibitors.
- NOACs demonstrate promising results, offering convenience and reduced monitoring needs.
- Challenges with NOACs include the lack of specific monitoring assays and readily available antidotes.
Conclusions:
- NOACs represent significant advancements in AF thromboprophylaxis.
- The choice of anticoagulant requires balancing efficacy, safety, and patient-specific factors.
- Further research is needed to address NOAC monitoring and reversal strategies.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...